Publikationen/Publications

Selected publications

1. Carpinteiro A, Kimmich C, Trajanova D, Hegenbart U, Hansen T, Holtick U, von Landenberg-Roberg V, Bohl SR, Teipel R, von Metzler I, Engelhardt M, Shumilov E, Steinhardt M, Reinhardt HC, Oubari S, Schönland S. Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. Hemasphere. 2026 Jun 16;10(6):e70389. doi: 10.1002/hem3.70389. eCollection 2026 Jun.
2. Naser E, Oubari S, Jakob J, Häupl B, Budeus B, Walkenfort B, Nowakowski M, Hessler G, Kühn C, Hasenberg M, Oellerich T, Reinhardt HC, Carpinteiro A. RNA-based full length immunoglobulin light chain sequencing reveals lambda constant domain mutations with potential implications for thermodynamic stability in light chain amyloidosis. Amyloid. 2026 Jun 4:1-15. doi: 10.1080/13506129.2026.2679153.
3. Settelmeier S, Agranovski D, Steinhardt M, Waydhas S, Gering I, Cejka V, Morbach C, Störk S, Willbold D, Küppers R, Vogel J, Michel L, Carpinteiro A, Reinhardt HC, Dodel R, Rassaf T, Ross AJ, Hendgen-Cotta UB. Transthyretin stabilizer therapy increases naturally-occurring antibodies in ATTR cardiomyopathy. Amyloid. 2026 Apr 6:1-17. doi: 10.1080/13506129.2026.2651299. Online ahead of print.
4. Martinez-Rivas G, Ayala MV, Bender S, Codo GR, Swiderska WK, Lampis A, Pedroza L, Merdanovic M, Sicard P, Pinault E, Richard L, Lavatelli F, Giorgetti S, Canetti D, Rinsant A, Kaaki S, Ory C, Oblet C, Pollet J, Naser E, Carpinteiro A, Roussel M, Javaugue V, Jaccard A, Bonaud A, Delpy L, Ehrmann M, Bridoux F, Sirac C. A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils. Nat Commun. 2025 Mar 27;16(1):2992. doi: 10.1038/s41467-025-58307-2.
5. Oubari S, Papathanasiou M, Michel L, Rassaf T, Thimm A, Hagenacker T, Ehling D, Wieczorek S, Naser E, Hegenbart U, Schönland S, Dührsen U, Reinhardt HC, Carpinteiro A. Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival. Ann Hematol. 2025 Mar;104(3):1777-1788. doi: 10.1007/s00277-025-06256-7. Epub 2025 Mar 22.
6. Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series. Blood. 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937.
7. Oubari S, Hegenbart U, Schoder R, Steinhardt M, Papathanasiou M, Rassaf T, Thimm A, Hagenacker T, Naser E, Duhrsen U, Reinhardt HC, Kortum M, Agis H, Schonland S, Carpinteiro A Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica. 2024 Jan 1;109(1):220-230. doi: 10.3324/haematol.2023.283325.
8. Hashemi Arani F, Kadow S, Kramer M, Keitsch S, Kirchhoff L, Schumacher F, Kleuser B, Rath PM, Gulbins E, Carpinteiro A. Sphingosine as a New Antifungal Agent against Candida and Aspergillus spp. Int J Mol Sci. 2022 Dec 7;23(24):15510. doi: 10.3390/ijms232415510.
9. Kadow S, Schumacher F, Kramer M, Hessler G, Scholtysik R, Oubari S, Johansson P, Hüttmann A, Reinhardt HC, Kleuser B, Zoratti M, Mattarei A, Szabò I, Gulbins E, Carpinteiro A. Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma. Cancers (Basel). 2022 Apr 13;14(8):1955. doi: 10.3390/cancers14081955.
10. Oubari S, Naser E, Papathanasiou M, Luedike P, Hagenacker T, Thimm A, Rischpler C, Kessler L, Kimmich C, Hegenbart U, Schönland S, Rassaf T, Reinhardt HC, Jöckel KH, Dürig J, Dührsen U, Carpinteiro A. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. Eur J Haematol. 2021 Oct;107(4):449-457. doi: 10.1111/ejh.13681. Epub 2021 Jul 9.
11. Carpinteiro A, Gripp B, Hoffmann M, Pöhlmann S, Hoertel N, Edwards MJ, Kamler M, Kornhuber J, Becker KA, Gulbins E. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021 Jan-Jun;296:100701. doi: 10.1016/j.jbc.2021.100701. Epub 2021 Apr 23.
12. Becker KA, Carpinteiro A, Hoffmann M, Pöhlmann S, Kornhuber J, Gulbins E. Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells. STAR Protoc. 2021 Mar 19;2(1):100356. doi: 10.1016/j.xpro.2021.100356. Epub 2021 Feb 3.
13. Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, Adams C, Carpinteiro E, Gulbins A, Keitsch S, Sehl C, Soddemann M, Wilker B, Kamler M, Bertsch T, Lang KS, Patel S, Wilson GC, Walter S, Hengel H, Pöhlmann S, Lang PA, Kornhuber J, Becker KA, Ahmad SA, Fassbender K, Gulbins E. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. Cell Rep Med. 2020 Nov 17;1(8):100142. doi: 10.1016/j.xcrm.2020.100142. Epub 2020 Oct 29.